In January 2026, the Saudi Food and Drug Authority (SFDA) took a decisive step forward in the Kingdom's rare disease agenda — granting orphan drug designations to Jascayd (nerandomilast) for idiopathic pulmonary fibrosis and Sephience for another rare condition. Simultaneously, Quoin Pharmaceuticals filed for Breakthrough Medicine Designation for QRX003, a potential world-first treatment for Netherton Syndrome. These milestones signal that Saudi Arabia is no longer on the sidelines of the global rare disease conversation.
For patients across the Kingdom living with rare and genetic disorders — many still undiagnosed — these developments carry real significance.
The Rare Disease Burden in Saudi Arabia
Rare diseases present a disproportionately high burden in Saudi Arabia compared to Western nations. High rates of consanguineous marriages (estimated at 50–60% in some regions) contribute to an elevated prevalence of rare genetic disorders, with approximately 80% of rare diseases being genetic in origin. The collective burden is estimated to rival that of type 2 diabetes — a sobering comparison that underscores the scale of unmet need.
Yet until recently, Saudi Arabia lacked a unified national rare disease strategy. There is no formal registry, no locally defined classification system, and limited specialized treatment centers. A 2023 multi-stakeholder workshop organized by Frontiers in Pharmacology documented these gaps in detail, calling for systemic reform.
SFDA's Orphan Drug Program: How It Works
The SFDA Orphan Drug Program, launched under Vision 2030's Health Sector Transformation Program, incentivizes pharmaceutical companies to develop treatments for rare diseases in the Kingdom. Key features include:
- Priority regulatory review — accelerated timelines for marketing authorization dossier evaluation
- Pre-submission meetings — early dialogue between drug developers and SFDA to streamline the pathway
- Market exclusivity — time-limited protection to encourage investment in therapies for small patient populations
- Dedicated regulatory pathway — a separate track from standard drug registration for medicines targeting serious or rare diseases with promising preliminary data
An orphan drug designation does not constitute product registration. It permits sponsors to submit a marketing authorization dossier through the dedicated pathway, with final approval following comprehensive technical evaluation.
January 2026: A Month of Milestones
Jascayd (Nerandomilast) — Boehringer Ingelheim
On January 29, 2026, the SFDA granted orphan drug designation to Jascayd (nerandomilast), developed by Boehringer Ingelheim, for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, debilitating lung disease with limited treatment options, and Jascayd represents a new phosphodiesterase 4B inhibitor mechanism that could meaningfully expand the therapeutic arsenal.
Sephience
On January 28, 2026 — one day earlier — the SFDA also granted orphan drug designation to Sephience, further demonstrating the Authority's intent to accelerate rare disease therapy access.
QRX003 for Netherton Syndrome — Quoin Pharmaceuticals
Perhaps the most compelling development: on January 20, 2026, Quoin Pharmaceuticals filed an application for Breakthrough Medicine Designation with the SFDA for QRX003, a topical treatment for Netherton Syndrome — a severe, lifelong inherited skin disorder with no approved treatment anywhere in the world.
If approved, QRX003 could be available in Saudi Arabia as early as H2 2026, making it potentially the world's first approved Netherton Syndrome therapy. The drug already holds Orphan Drug and Pediatric Rare Disease designations from the U.S. FDA, plus EU Orphan Drug Designation. Quoin has partnered with Genpharm for MENA distribution to ensure rapid patient access.
The Breakthrough Medicine Designation Pathway
The SFDA's Breakthrough Medicine Designation complements the orphan drug program. To qualify, a drug must target a serious or life-threatening condition with unmet needs, demonstrate significant advantage over current treatments, show a positive benefit/risk balance, and not yet be registered with any stringent regulatory authority.
The two-step process involves eligibility review by a scientific committee (within 15 working days), followed by dossier submission through the Saudi Drug Registration system in eCTD format. Applications can be filed as early as end of Phase 2, enabling significantly earlier market entry — particularly valuable for rare disease therapies that may never achieve conventional Phase 3 sample sizes.
Challenges That Remain
Despite the momentum, significant barriers persist:
- No national rare disease strategy: Saudi Arabia still lacks a comprehensive plan with defined governance, funding, and accountability mechanisms.
- No standardized local definitions: There is no Saudi-specific definition of "rare disease" or "orphan drug," creating policy ambiguity — though a 2025 PMC workshop began addressing this gap.
- Limited diagnostic infrastructure: The genetic testing market is growing at 14.8% CAGR (projected to reach $16.6 million by 2030) but still trails demand.
- Healthcare professional awareness: Many clinicians outside specialized centers have limited rare disease exposure, contributing to diagnostic delays — sometimes by years.
- Reimbursement uncertainty: Even after approval, pricing negotiations and formulary inclusion can add months to real-world patient access.
Vision 2030 and the Road Ahead
The SFDA's actions align with Vision 2030's priorities: expanding specialized healthcare capacity, reducing reliance on overseas treatment, attracting international pharmaceutical investment, and leveraging Saudi Arabia's unique genetic landscape for precision medicine. Multi-stakeholder workshops in 2023 and 2025 have produced actionable recommendations — accrediting centers of excellence, streamlining regulation, enhancing medical education, and fostering international collaborations. Early 2026 suggests these are gaining institutional traction.
What This Means for Patients and Industry
For patients, these designations represent tangible hope — a potential first-in-world Netherton Syndrome therapy, new IPF options, and a regulatory authority visibly accelerating access.
For pharma and biotech, Saudi Arabia is signaling it is open for business in the rare disease space. A large, genetically predisposed patient population, accelerating regulatory frameworks, and Vision 2030 investment create a compelling market access case. Companies with orphan drug pipelines should actively explore SFDA pathways and local distribution partnerships.
For policymakers, the next step is connecting regulatory momentum to a comprehensive national strategy — linking SFDA designations to diagnostic infrastructure, patient registries, reimbursement frameworks, and centers of excellence.
Saudi Arabia's rare disease landscape is at an inflection point. The question is no longer whether the Kingdom will engage with the global orphan drug ecosystem — it is how quickly and comprehensively it will do so.